Institut Pasteur

Centre National De La Recherche Scientifique

Commissariat &#xc0; L'&#xc9;nergie Atomique Et Aux &#xc9;nergies Alternatives

F. Hoffmann-la Roche Ag

Institut National De La Sante Et De La Recherche Medicale

United States of America, As Represented by the Secretary of Agriculture

Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement

Other

Assistance Publique-hopitaux De Paris

Institut National De La Recherche Agronomique

Institut National De La Recherche Agronomique (inra)

Université De Paris

Universite Paris 13 - Paris Nord

Centre National De La Recherche Scientifique-cnrs

Sylvie Bay

Pierre Lafaye

Fiona Grueninger

Christian Czech

Tengfei Li

Benoit Delatour

Matthias Vandesquille

Marc Dhenain

Charles Duyckaerts

Claude Leclerc

Richard Lo-Man

Franck Biet

John P Bannantine

Gilles Etienne

Daniele Cantacuzene

Antonino Nicoletti

Giuseppina Caligiuri

Jean-Marc Reyrat

Dominique Le Guludec

Benoît Delatour

Jonathan Vigne

Sophie Vicher-Guerre

Teresa Freire

The present invention is directed to an isolated synthetic tripeptide of formula H-D-Phe-N-Methyl-L-Val-L-Ala-OMe (SEQ ID NO: 1), or a derivative thereof, and to the corresponding lipotripeptides, which are specific tosubsp.(Map) S-type strain, as well as derivatives and conjugates thereof. The invention also concerns the use of these antigens in different methods and tests for detecting Map infection, especially by detecting humoral response and cell mediated response of infected animals. The invention is also directed to a genetic signature of Map and a mass spectrometry and NMR spectroscopy signature of Map presence or infection.

Antigenic tripeptides derived fromsubsp.S-type strains, derivatives and uses thereof

The present invention is directed to an isolated synthetic tripeptide of formula H-D-Phe-N-Methyl-L-Val-L-Ala-OMe (SEQ ID NO:1), or a derivative thereof, and to the corresponding lipotripeptides, which are specific tosubsp.(Map) S-type strain, as well as derivatives and conjugates thereof. The invention also concerns the use of these antigens in different methods and tests for detecting Map infection, especially by detecting humoral response and cell mediated response of infected animals. The invention is also directed to a genetic signature of Map and a mass spectrometry and NMR spectroscopy signature of Map presence or infection.

Antigenic tripeptides derived fromsubsp.s-type strains, derivatives and uses thereof

The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.

Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof

Disclosed is CD31for use as a molecular imaging target in the molecular imaging of an inflammatory condition. Administering the radiolabeled peptide P8RI as CD31ligand in different rat models of inflammation indeed showed that CD31is present on activated cells in a quantity allowing a detectable signal, whereas the noise signal corresponding to CD31present on activated circulating cells and on other organs or cells not involved in inflammation was little. Also disclosed is a labeled CD31ligand and the use thereof as a molecular imaging agent in the molecular imaging of an inflammatory condition. The molecular imaging of inflammatory sites particularly allows determining whether a subject suffers from or is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment.

CD31as a molecular target for imaging of inflammation

The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B)(I) wherein M, T, B and n ore as defined in claim

Method for preparing multiple antigen glycopeptide carbohydrate conjugates

The present invention relates to an oligopeptide and conjugates thereof. The present invention also relates to the use of these oligopeptide conjugates for treating or diagnosing disorders mediated by amyloid &#x3b2; deposits. Finally, the present invention also relates to a coupling method for obtaining oligopeptide coupled with a substance of interest (functional conjugates).

Oligopeptide and methods for producing conjugates thereof

The present invention relates to variable domain of a camelid heavy-chain antibodies directed to amyloid &#x3b2; and conjugates thereof. The present invention also relates to the use of these antibody conjugates for treating or diagnosing disorders mediated by amyloid &#x3b2; deposits.

Camelid single-domain antibody directed against amyloid beta and methods for producing conjugates thereof

The present invention relates to mucin glycoconjugates, and to a process of producing mucin glycoconjugates. It relates to the biological, pharmaceutical and medical applications thereof. The invention notably provides mucin glycoconjugates which do not require a protein carrier, such as KHL, to induce an immune response (anti-Tn IgG).

Enzymatic large-scale synthesis of mucin glyconjugates, and immunogenic applications thereof

The current invention relates to the diagnosis and treatment of diseases resulting from infections bysubsp.. In particular the invention relates to the use of an antigen selected among (a) a synthetic peptide 5P having the following formula: DPhe-NMeVal-Ile-Phe-Ala-OMe (SEQ ID NO: 1); (b) a lipopeptide L5P consisting of the synthetic peptide a) wherein the N-terminal phenylalanine residue is N-acylated with an eicosanoic acid acyl chain; (c) a variant of peptide a) or lipopeptide b) able to react with anti-antibodies; for in vitro detection or quantification of specific anti-antibodies in a biological sample.

[object Object]

The invention of the present application relates to a method for obtaining antibodies directed against a carbohydrate moiety contained in a carbohydrate peptide conjugate, by administering to a subject a composition containing a carbohydrate peptide conjugate and collecting the antibodies directed against the said carbohydrate moiety from a serum previously obtained from the subject.

Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof

Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof

Growing community of inventors

Paris, France

Sylvie Bay